ENZYCHEM LIFESCIENCES CORPORATION |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,880 KRW | +0.70% |
|
+6.88% | +3.41% |
| Apr. 05 | Enzychem Lifesciences Corporation announces an Equity Buyback for KRW 10,000 million worth of its shares. | CI |
| Apr. 05 | Enzychem Lifesciences Corporation authorizes a Buyback Plan. | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 759,328 | 553,292 | 869,255 | 457,391 | 139,497 | 154,649 |
| Enterprise Value (EV) 1 | 728,179 | 510,960 | 821,818 | 414,782 | -15,580 | 22,956 |
| P/E ratio | -51.9 x | -33.5 x | -48.9 x | -16.9 x | -5.24 x | -16.5 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 24.5 x | 17.6 x | 33.7 x | 19.9 x | 5.24 x | 2.03 x |
| EV / Revenue | 23.5 x | 16.2 x | 31.8 x | 18.1 x | -0.58 x | 0.3 x |
| EV / EBITDA | -56.9 x | -35.3 x | -48.1 x | -22.2 x | 1.27 x | -2.05 x |
| EV / FCF | -69.2 x | -42.8 x | -73.8 x | -18.4 x | 0.48 x | -1.68 x |
| FCF Yield | -1.44% | -2.34% | -1.35% | -5.43% | 209% | -59.4% |
| Price to Book | 13 x | 7.49 x | 12 x | 6.14 x | 0.69 x | 0.8 x |
| Nbr of stocks (in thousands) | 46,066 | 47,156 | 49,483 | 49,988 | 84,288 | 85,066 |
| Reference price 2 | 16,483 | 11,733 | 17,567 | 9,150 | 1,655 | 1,818 |
| Announcement Date | 3/14/19 | 3/11/20 | 3/23/21 | 3/23/22 | 3/21/23 | 3/20/24 |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 31,034 | 31,469 | 25,818 | 22,975 | 26,638 | 76,039 |
| EBITDA 1 | -12,796 | -14,456 | -17,072 | -18,643 | -12,273 | -11,221 |
| EBIT 1 | -14,329 | -16,402 | -19,107 | -20,754 | -14,662 | -14,733 |
| Operating Margin | -46.17% | -52.12% | -74.01% | -90.33% | -55.04% | -19.38% |
| Earnings before Tax (EBT) 1 | -14,281 | -16,676 | -19,232 | -29,504 | -25,581 | -9,879 |
| Net income 1 | -14,420 | -16,879 | -17,507 | -27,865 | -25,093 | -9,326 |
| Net margin | -46.47% | -53.64% | -67.81% | -121.28% | -94.2% | -12.27% |
| EPS 2 | -317.6 | -350.3 | -359.0 | -540.0 | -316.0 | -110.0 |
| Free Cash Flow 1 | -10,517 | -11,952 | -11,130 | -22,543 | -32,617 | -13,645 |
| FCF margin | -33.89% | -37.98% | -43.11% | -98.12% | -122.45% | -17.95% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/14/19 | 3/11/20 | 3/23/21 | 3/23/22 | 3/21/23 | 3/20/24 |
1KRW in Million2KRW
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 31,148 | 42,332 | 47,437 | 42,609 | 155,077 | 131,693 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -10,517 | -11,952 | -11,130 | -22,543 | -32,617 | -13,645 |
| ROE (net income / shareholders' equity) | -34.6% | -25.4% | -23.9% | -37.9% | -18.2% | -4.74% |
| ROA (Net income/ Total Assets) | -17.2% | -13.5% | -11.4% | -10.1% | -4.81% | -4.01% |
| Assets 1 | 83,608 | 125,166 | 153,043 | 275,930 | 521,166 | 232,498 |
| Book Value Per Share 2 | 1,268 | 1,567 | 1,464 | 1,490 | 2,390 | 2,275 |
| Cash Flow per Share 2 | 77.70 | 48.50 | 37.50 | 55.70 | 91.20 | 182.0 |
| Capex 1 | 3,617 | 2,832 | 2,836 | 5,818 | 7,957 | 2,248 |
| Capex / Sales | 11.65% | 9% | 10.98% | 25.32% | 29.87% | 2.96% |
| Announcement Date | 3/14/19 | 3/11/20 | 3/23/21 | 3/23/22 | 3/21/23 | 3/20/24 |
1KRW in Million2KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +3.41% | 116M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- A183490 Stock
- Financials Enzychem Lifesciences Corporation
